Print

BIOSAFE Releases the First At-Home Diabetes Risk Assessment  
12/11/2007 11:12:22 AM

LAKE FOREST, Ill., Dec. 11 /PRNewswire/ -- BIOSAFE Medical Technologies, Inc. announced today the development of the first consumer test to evaluate diabetes risk. The BIOSAFE Diabetes Risk Assessment is a two-part process comprised of an immediate fasting glucose reading and a mail-in laboratory analysis for hemoglobin A1c, a blood glucose marker for the previous ninety-day period. Samples for both tests can be either professionally collected or self-collected through the use of a simple finger-nick collection kit. Taken in combination, these two results become a reliable indicator of diabetes or a pre-diabetes condition.

Type 2 diabetes (non-insulin dependent diabetes) affects more than 20 million Americans and is the most common form of the disease. However, because diabetes exhibits few if any symptoms until its advanced stages, millions more are in danger of contracting the disease and are unaware of it. When blood glucose (sugar) levels are higher than normal, but not yet high enough to be classified as diabetes, a condition known as pre-diabetes exists.

If discovered early, a person with pre-diabetes can avoid the disease through education, diet, exercise, and drugs.

"Diabetes is a debilitating, crippling, and life-shortening disease whose most serious complications can be prevented with early detection. The BIOSAFE Diabetes Risk Assessment is a common-sense approach to early detection of a potentially dangerous condition," said Jack Maggiore, PhD, president of BIOSAFE Laboratories, Inc. "Despite decades of medical advances for the treatment of diabetes, millions of people remain unknowingly undiagnosed and at risk for the disease. By making this quick, convenient and inexpensive kit available to consumers, we are confident that those who are identified as being in a pre-diabetic state will work with their physicians to implement dietary and healthy lifestyle changes to avoid the onset of diabetes and its catastrophic complications, such as heart disease, blindness, and kidney failure."

BIOSAFE Medical Technologies, Inc. is a world leader in the development of micro blood sample testing technology. Located in Chicago, Illinois, BIOSAFE Laboratories, Inc. is a subsidiary of BIOSAFE Medical Technologies, Inc., and develops, manufactures, and processes health monitoring and screening products for the consumer, physician, health screening, occupational health, pharmaceutical, disease-management, and medical research markets.

For more information, contact Henry Warner at 847-234-8111,

fax 847-234-8222, or email hwarner@ebiosafe.com.

CONTACT: Henry Warner of BIOSAFE Medical Technologies, Inc.,
+1-847-234-8111, fax, +1-847-234-8222, hwarner@ebiosafe.com

Web site: http://www.ebiosafe.com/


//-->